Publications by authors named "D Pariser"
Background: Botulinum neurotoxins used in aesthetic medicine require reconstitution before administration, which may be inconvenient and present errors among injectors.
Objectives: Evaluate the efficacy and safety of ready-to-use nivobotulinumtoxinA liquid formulation for the treatment of glabellar lines (GL) with/without treatment of lateral canthal lines (LCL).
Methods: Two multicenter, phase 3, double-blind, randomized trials enrolled participants with moderate-to-severe GL (Study 001) or moderate-to-severe GL+LCL (Study 005).
Introduction: The Atopic Dermatitis Control Tool (ADCT) assesses six concepts regarding patient-perceived control of atopic dermatitis (AD) in adults and adolescents with AD. This study aimed to develop two modified ADCT versions, one for children with AD aged 8-11 years and another for caregivers of children with AD aged 6 months to 11 years.
Methods: Following the US Food and Drug Administration patient-reported outcomes guidance, the ADCT was modified to produce draft Child and Caregiver ADCT versions, maintaining the original six concepts.
Article Synopsis
- * In a trial with 120 participants, those treated with the TAT-Patch showed a significant improvement in sweating severity compared to those who received a sham patch, with 64% achieving better results after four weeks.
- * The TAT-Patch led to meaningful reductions in sweat production and improved quality of life, and while some mild side effects were noted, the treatment was generally well tolerated with no serious adverse events.
Article Synopsis
- Hidradenitis suppurativa (HS) is a chronic skin condition, and secukinumab has shown sustained effectiveness and good safety for treating moderate-to-severe HS, though its performance in previously treated patients is unclear.
- The study analyzes data from two phase III trials (SUNSHINE and SUNRISE) to assess how prior exposure to biologics influences the efficacy and safety of secukinumab in HS patients.
- Results showed that secukinumab was more effective than placebo at 16 weeks for both biologic-experienced and biologic-naïve patients, indicating it remains a viable treatment option regardless of prior biologic treatment.
Background: Actinic keratoses (AKs) are precancerous, dysplastic, epidermal lesions caused by chronic sun exposure that may progress to squamous cell carcinoma. Aminolevulinic acid 20% solution with blue light photodynamic therapy (ALA-PDT) has previously been shown to be superior to vehicle plus PDT (VEH-PDT) for treatment of AKs of the face, scalp, and upper extremities.
Objective: We report detailed patient satisfaction data for ALA-PDT.